Pers Med News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pers med. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pers Med Today - Breaking & Trending Today

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

Targeting CLDN18.2 with zolbetuximab significantly prolonged progression-free survival
and overall survival when combined with mFOLFOX6 versus placebo plus mFOLFOX6 in patients
with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic
gastric or gastro-oesophageal junction adenocarcinoma. Zolbetuximab plus mFOLFOX6
might represent a new first-line treatment in these patients. ....

Van Cutsem , Japanese Gastric Cancer Association , Chinese Society Of Clinical Oncology , Global Burden , Disease Study , Chinese Society , Clinical Oncology , Gastric Cancer Treatment Guidelines , Clin Med , Clin Oncol , Practice Guideline , Pers Med , Cell Biol , Cancer Res ,